Europe preventive vaccines market was valued at $18.02 billion in 2022 and will grow by 5.1% annually over 2022-2032, driven by the rising prevalence of several infectious diseases, rising R&D investment and technological advancement in vaccination technologies, rising need for preventive vaccines such as COVID-19 vaccines, and the increasing healthcare expenditure.
Highlighted with 62 tables and 55 figures, this 142-page report “Europe Preventive Vaccines Market 2022-2032 by Vaccine Type, Disease, Administration, Patient, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• mRNA Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pneumococcal Disease
• Poliovirus
• Hepatitis
• Influenza
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Human Papilloma Virus
• COVID-19
• Other Diseases
By Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
By Patient, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Vaccine Type, Disease, and Administration over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter’s Fiver Forces Analysis 44
3 Segmentation of Europe Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57
4 Segmentation of Europe Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68
5 Segmentation of Europe Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75
6 Segmentation of Europe Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80
7 European Market 2022-2032 by Country 82
7.1 Overview of European Market 82
7.2 Germany 85
7.3 U.K. 88
7.4 France 91
7.5 Spain 94
7.6 Italy 97
7.7 Russia 100
7.8 Rest of European Market 103
8 Competitive Landscape 105
8.1 Overview of Key Vendors 105
8.2 New Product Launch, Partnership, Investment, and M&A 108
8.3 Company Profiles 109
AstraZeneca plc 109
Bavarian Nordic A/S 111
China National Biotec Group Company Ltd. 114
CSL Ltd. 116
Daiichi Sankyo Co. Ltd 118
Emergent BioSolutions Inc. 120
GlaxoSmithKline plc 122
Johnson & Johnson 126
Merck & Co. 128
Moderna Inc. 130
Novavax, Inc. 131
Pfizer Inc. 133
Sanofi SA 137
Takeda Pharmaceutical Co. Ltd. 140
RELATED REPORTS 142
List of Tables:
Table 1. Snapshot of Europe Preventive Vaccines Market in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Economic Outlook, 2021-2023 24
Table 4. Scenarios for Economic Impact of Ukraine Crisis 28
Table 5. World Health Spending by Region, $ bn, 2013-2020 36
Table 6. Main Product Trends and Market Opportunities in Europe Preventive Vaccines Market 40
Table 7. Europe Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 48
Table 8. Europe Preventive Vaccines Market by Disease, 2022-2032, $ mn 58
Table 9. Europe Preventive Vaccines Market by Administration, 2022-2032, $ mn 69
Table 10. Europe Preventive Vaccines Market by Patient, 2022-2032, $ mn 76
Table 11. Europe Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn 79
Table 12. Europe Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn 81
Table 13. Europe Preventive Vaccines Market by Country, 2022-2032, $ mn 84
Table 14. Germany Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 86
Table 15. Germany Preventive Vaccines Market by Disease, 2022-2032, $ mn 86
Table 16. Germany Preventive Vaccines Market by Administration, 2022-2032, $ mn 87
Table 17. U.K. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 89
Table 18. U.K. Preventive Vaccines Market by Disease, 2022-2032, $ mn 89
Table 19. U.K. Preventive Vaccines Market by Administration, 2022-2032, $ mn 90
Table 20. France Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 92
Table 21. France Preventive Vaccines Market by Disease, 2022-2032, $ mn 92
Table 22. France Preventive Vaccines Market by Administration, 2022-2032, $ mn 93
Table 23. Spain Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 95
Table 24. Spain Preventive Vaccines Market by Disease, 2022-2032, $ mn 95
Table 25. Spain Preventive Vaccines Market by Administration, 2022-2032, $ mn 96
Table 26. Italy Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 98
Table 27. Italy Preventive Vaccines Market by Disease, 2022-2032, $ mn 98
Table 28. Italy Preventive Vaccines Market by Administration, 2022-2032, $ mn 99
Table 29. Russia Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 101
Table 30. Russia Preventive Vaccines Market by Disease, 2022-2032, $ mn 101
Table 31. Russia Preventive Vaccines Market by Administration, 2022-2032, $ mn 102
Table 32. Preventive Vaccines Market in Rest of Europe by Country, 2022-2032, $ mn 104
Table 33. AstraZeneca plc: Company Snapshot 109
Table 34. AstraZeneca plc: Business Segmentation 110
Table 35. AstraZeneca plc: Product Portfolio 110
Table 36. Bavarian Nordic A/S: Company Snapshot 111
Table 37. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 112
Table 38. China National Biotec Group Company Ltd.: Company Snapshot 114
Table 39. CSL Ltd.: Company Snapshot 116
Table 40. Daiichi Sankyo Co. Ltd.: Company Snapshot 118
Table 41. Emergent BioSolutions Inc.: Company Snapshot 120
Table 42. GlaxoSmithKline: Company Snapshot 122
Table 43. GlaxoSmithKline: Business Segmentation 123
Table 44. GlaxoSmithKline: Product Portfolio 124
Table 45. GlaxoSmithKline: Revenue, 2018-2020, $ bn 125
Table 46. GlaxoSmithKline: Recent Developments 125
Table 47. Johnson & Johnson: Company Snapshot 126
Table 48. Johnson & Johnson: Business Segments 127
Table 49. Merck & Co., Inc.: Company Snapshot 128
Table 50. Merck & Co., Inc.: Business Segmentation 128
Table 51. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 129
Table 52. Moderna Inc.: Company Snapshot 130
Table 53. Novavax, Inc.: Company Snapshot 131
Table 54. Pfizer Inc.: Company Snapshot 133
Table 55. Pfizer Inc.: Business Segmentation 134
Table 56. Pfizer Inc.: Product Portfolio 135
Table 57. Pfizer Inc.: Revenue, 2018-2020, $ bn 136
Table 58. Pfizer Inc.: Recent Developments 136
Table 59. Sanofi: Company Snapshot 137
Table 60. Sanofi: Business Segmentation 137
Table 61. Sanofi: Revenue, 2018-2020, $ bn 139
Table 62. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 140
